Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report

Respir Investig. 2024 Jan;62(1):13-15. doi: 10.1016/j.resinv.2023.09.006. Epub 2023 Nov 3.

Abstract

Osimertinib has demonstrated efficacy as the first- and second-line treatment for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. However, EGFR-mutant NSCLC cells often acquire resistance to osimertinib. V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation (BRAF V600E) was detected in a re-biopsy (LC-SCRUM-TRY testing) of a patient with advanced lung adenocarcinoma who was resistant to osimertinib treatment. Currently, the patient is receiving dabrafenib/trametinib combination therapy and is under observation; a slight shrinking effect of cancer has been observed.

Keywords: BRAF V600E; EGFR; Lung cancer; Osimertinib.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides*
  • Adenocarcinoma of Lung* / drug therapy
  • Adenocarcinoma of Lung* / genetics
  • Aniline Compounds*
  • Animals
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • ErbB Receptors / genetics
  • Humans
  • Indoles*
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Mice
  • Mutation
  • Oncogenes
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf / genetics
  • Pyrimidines*

Substances

  • Proto-Oncogene Proteins B-raf
  • osimertinib
  • ErbB Receptors
  • Protein Kinase Inhibitors
  • Acrylamides
  • Aniline Compounds
  • Indoles
  • Pyrimidines